Depression, craving, and substance use following a randomized trial of mindfulness-based relapse prevention.

Study at a glance

Characteristics	Randomized controlled trial Peer reviewed
Population	Individuals with substance use disorders
Intervention	Mindfulness-based relapse prevention
Topics	Depression Meditation
Key findings	MBRP significantly reduced depression and craving relative to treatment as usual, but did not significantly affect substance use.

Other randomized controlled trials on depression, most cited first.

Study	Year	Design	Participants
A Randomized Trial of an N-methyl-D-aspartate Antagonist in Treatment-Resistant Major Depression Subjects with DSM-IV major depression (treatment resistant)	2006	Randomized, placebo-controlled, double-blind crossover study	n = 18
Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. Recovered recurrently depressed patients	2000	Randomized controlled trial	n = 145
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial Cancer patients with life-threatening diagnoses and symptoms of depression and/or anxiety	2016	Randomized controlled trial	n = 51
Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial Patients with cancer-related anxiety and depression	2016	Double-blind, placebo-controlled, crossover trial	n = 29
Mindfulness-Based Cognitive Therapy for Depression: Replication and Exploration of Differential Relapse Prevention Effects. Recovered recurrently depressed patients	2004	Randomized controlled trial	n = 73